Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City...
-
Upload
david-ira-farmer -
Category
Documents
-
view
216 -
download
0
Transcript of Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City...
![Page 1: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/1.jpg)
Anxiety and Pain Control 2007
John A. Yagiela, DDS, PhD
Utah Dental Association
Salt Lake CityFebruary 9, 2007
![Page 2: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/2.jpg)
Local Anesthesia Topics
Articaine: efficacy versus neurotoxicity
Advances in local anesthetic metabolism
Ropivacaine as a dental anesthetic Oraqix, the topical anesthetic for periodontics
NV-101 (phentolamine mesylate), a new reversal agent for local anesthesia
![Page 3: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/3.jpg)
Articaine Hydrochloride (Septocaine)
Old new drug Thiophene-based amide Metabolized by plasma carboxyesterase
Low maximum dosage; low accumulation with repeated dosing
4% solution more effective than 2% lidocaine, both with epinephrine?
Increased incidence of nerve damage
![Page 4: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/4.jpg)
Articaine
CH 3
HNHC
CH 3O
CH
H
N
C 73
S
COOCH 3
Prilocaine
CH 3
HNHC
CH 3O
CH
H
N
C 73
Articaine (Septocaine, Zorcaine): a thiophene
derivative
![Page 5: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/5.jpg)
0 10 20 30 40 50 60 70 80 900
50
100
150
200
250
300
∆ Voltage (V)
Time (min)
Lid-2%-H Ult-2%-L Ult-2%-H Ult-4%-L Ult-4%-H
Mean Sensory Voltage: First Premolar
![Page 6: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/6.jpg)
VAS pain scores
Parameter Simple Complex Simple Complex
Subjects (n) 674 207 338 104
Mean (mm) 3 5 4 6
Median (mm) 0 2 0 2
Range (mm) 0-90 0-73 0-90 0-64
4% A + Epi 2% L + Epi
Malamed SF, et al. J Am Dent Assoc 131:635-42, 2000
![Page 7: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/7.jpg)
Studies showing increased efficacy of
articaine
Potocnik et al. J Dent Res 2006;85:162-6. Rat sural nerve study 2% and 4% articaine better than 2% and 4% lidocaine and 3% mepivacaine at blocking A fibers (but not C fibers)
Kanaa et al. J Endod 2006;32:296-8. Randomized double-blind cross-over study using electronic pulp tester
Articaine more effective than lidocaine after mandibular buccal infiltration anesthesia (65% vs. 39%)
![Page 8: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/8.jpg)
The efficacy question
No proof of increased effectiveness in double-blind clinical trials using standard injections
No clinical trial with sufficient power to distinguish small differences
If 97.5% versus 95% efficacy and 40 patients per week,
one less failure per week
![Page 9: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/9.jpg)
Local anesthesia use in Germany (1996)
2%
3%
4%91%ArticaineLidocaineMepivacaineOthers
![Page 10: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/10.jpg)
Local anesthesia use in Canada (1999)
12%
6%4%
46% 32%
ArticainePrilocaineLidocaineMepivacaineBupivacaine
![Page 11: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/11.jpg)
Haas, DA, Lennon D: A 21 year retrospective study of reports of paresthesia following local anesthetic administration. J Can Dent Assoc 61:319-30, 1995.
Study of reports to the Professional Liability Program of Ontario, Canada (1973-1993)
Surgery cases excluded 143 reports (lip, 42; tongue, 92; both, 9)
No significant effect of age, gender, or needle gauge
![Page 12: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/12.jpg)
Reported cases of paresthesiaby year
0
5
10
15
20
25
1970 1980 1990 2000
Haas DA, Lennon D: J Can Dent Assoc 61:297-304, 1995
Articainemarketed
![Page 13: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/13.jpg)
Incidence data
Haas DA, Lennon D: J Can Dent Assoc 61:297-304, 1995
Articaine and prilocaine: 91% of cases
1993 incidence by agent Articaine: 1/440,000 Prilocaine: 1/588,000 Lidocaine: none Mepivacaine: none
![Page 14: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/14.jpg)
Hillerup S, Jensen R: Nerve injury caused by mandibular block analgesia. Int J Oral Maxillofac Surg 35:437-43, 2006.
Consecutive patients with injection injury to oral branches of trigeminal nerve 1997-2004
Referrals from colleagues and Danish Dental Association’s Patient Insurance Scheme (covering all dentists)
patients with unilateral injection injury: 40 lingual nerve; 10 inferior alveolar; 2 both
![Page 15: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/15.jpg)
Cases of nerve injury by year
Articainemarketed
Hillerup S, Jensen R: Int J Oral Maxillofac Surg 35:437-43, 2006
![Page 16: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/16.jpg)
Incidence data
Articaine : 55% of cases 2001-2002 incidence data
Articaine: 20 times higher incidence than other local anesthetics combined
Hillerup S, Jensen R: Int J Oral Maxillofac Surg 35:437-43, 2006
![Page 17: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/17.jpg)
Johnson ME, Saenz JA, DaSilva AD, et al: Effect of local anesthetic on neuronal cytoplasmic calcium and plasma membrane lysis (necrosis) in a cell culture model. Anesthesiology 97:1466-76, 2002
NDE7 neurons derived from dorsal root ganglion loaded with fura-2
Cells exposed to lidocaine 0.1%-5% for 60 min
Fluorescence microscopy for Ca2+ and cell death during exposure period
![Page 18: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/18.jpg)
Effect of lidocaine on intracellular Ca2+
Johnson: Anesthesiology 97:1466-76, 2002
![Page 19: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/19.jpg)
Effect of lidocaine on neuronal survival
Johnson: Anesthesiology 97:1466-76, 2002
![Page 20: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/20.jpg)
Kishimoto T, Bollen AW, Drasner K: Comparative spinal neurotoxicity of prilocaine and lidocaine. Anesthesiology 97:1250-3, 2002.
Rats received intrathecal infusions of 2.5% prilocaine, 2.5% lidocaine, or normal saline (n=30/group)
Tail-flick test day 4 Histopathologic examination day 7
![Page 21: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/21.jpg)
Comparative spinal neurotoxicity of prilocaine and lidocaine
Kishimoto et al: Anesthesiology 97:1250-3, 2002
![Page 22: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/22.jpg)
Postulated mechanism for nerve injury
![Page 23: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/23.jpg)
![Page 24: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/24.jpg)
Deficits related to anesthetic and vasoconstrictor concentrations
Selander et al. Acta Anaesthesiol Scand 1979;23:127-36. Differing concentrations of bupivacaine with and without epinephrine injected into and around sciatic nerve fascicles in rabbits
Injection beneath epineurium resulted no injury except with excessive bupivacaine concentrations
Injection beneath perineurium resulted in concentration- and vasoconstrictor-dependent axonal degeneration
![Page 25: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/25.jpg)
Intrafascicular injection causes
neurologic deficits Hadzic et al. Reg Anesth Pain Med 2004;29:417-23. 4 mL 2% lidocaine with 1:25,000 epinephrine injected into and around sciatic nerve fascicles in dogs in 1 min
Injection beneath epineurium resulted in little injection pressure and no injury
Injection beneath perineurium resulted in high injection pressure and axonal degeneration
![Page 26: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/26.jpg)
Summary of findings Statistical association of 4% local anesthetic solutions with higher incidence of damage
Local anesthetics are neurotoxic in clinical concentrations
Neurotoxicity is concentration dependent Clinically used local anesthetics show similar inherent neurotoxicity
The perineurium serves as a barrier to local anesthetic distribution
Intrafascicular injection appears to be required for damage
The lingual nerve has as few as 1 fascicle
![Page 27: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/27.jpg)
Local Anesthetic Metabolism
Role of cytochrome P450 enzymes
![Page 28: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/28.jpg)
Principal drug metabolizing enzymes
![Page 29: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/29.jpg)
Lidocaine metabolism
![Page 30: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/30.jpg)
Lidocaine pharmacokinetics CYP1A2 is the major determinant of lidocaine metabolism in patients with normal liver function
Liver disease reduces CYP1A2 activity
Fluvoxamine (Luvox) inhibits oxidative metabolism of lidocaine, MEGX, and GX by 60%
Orlando et al. Clin Pharmacol Ther 2004;75:80-8.
![Page 31: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/31.jpg)
Lidocaine pharmacokinetics (2) CYP3A4 is normally a minor determinant of lidocaine metabolism in patients with normal liver function
Liver disease may not significantly reduce CYP3A4 activity
Erythromycin inhibits lidocaine metabolism by 15%-20%
Orlando et al. Br J Clin Pharmacol 2003;55:86-93.
![Page 32: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/32.jpg)
Effect of fluvoxamine on lidocaine pharmacokinetics
ParameterPlaceb
oFluvoxami
nePlaceb
oFluvoxami
ne
CL (mL/min•k
g)12.1 4.85* 4.21* 3.65*
Vss (L/kg) 1.87 1.57 2.87* 2.55*T1/2 (hr) 2.15 4.94* 9.31† 9.17†
Healthy subjects Cirrhotic patients
Orlando et al. Clin Pharmacol Ther 2004;75:80-8.
![Page 33: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/33.jpg)
Effect of erythromycin on lidocaine pharmacokinetics
ParameterPlaceb
oErythrom.
Placebo
Erythrom.
CL (mL/min•k
g)9.83 8.15* 5.46* 4.26*,†
Vss (L/kg) 1.47 1.34 2.44* 2.42*T1/2 (hr) 2.23 2.80* 5.77† 7.74*,†
Healthy subjects Cirrhotic patients
Orlando et al. Br J Clin Pharmacol 2003;55:86-93.
![Page 34: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/34.jpg)
Lidocaine pharmacokinetics influenced by stress
Rats without stress compared to rats experiencing mandibular osteotomy, cold swimming stress, experimental arthritis
Lidocaine (3 mg/kg) administered every 2 hr for 5 doses.
Serum lidocaine measured 2 hr after last dose
Saranteas et al. J Oral Maxillofac Surg 2004;62:858-62.
![Page 35: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/35.jpg)
Lidocaine pharmacokinetics influenced by stress
Saranteas et al. J Oral Maxillofac Surg 2004;62:858-62.
ControlOsteotom
y Cold
swimming
Exp. arthriti
s
Serum lidocain
e(µg/mL)
5.9 ± 1.1
9.3 ± 0.6*
8.2 ± 0.2*
8.9 ± 0.7*
Mandible (µg/g)
1.1 ± 0.1
0.6 ± 0.7*
0.6 ± 0.7*
0.8 ± 0.2*
![Page 36: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/36.jpg)
Anesthetic efficacy of ropivacaine without vasoconstrictor for
inferior alveolar nerve block
El-Sharrawy EA, Yagiela JA. Anesth Prog
2006;53:3-7.
![Page 37: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/37.jpg)
Study design Randomized parallel-group, dose-ranging study of 72 ASA I patients receiving mandibular 3rd molar extraction
One cartridge for inferior alveolar-lingual nerve block and buccal infiltration
Re-injection up to two times if failure of previous injections
El-Sharrawy and Yagiela. Anesth Prog 2006;53:3-7.
![Page 38: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/38.jpg)
Onset time (soft-tissue)
![Page 39: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/39.jpg)
Rating
Patient Response During Extraction
1 No pain throughout procedure
2 Some discomfort during procedure, but reinjection not necessary.
3 Second injection necessary, but no pain afterward.
4 Some discomfort afterward, but third injection not necessary.
5 Third injection necessary, but no pain afterward.
6 Some discomfort after third injection, but procedure completed.
7 Discomfort after third injection, and procedure postponed.
Quality of anesthesia
![Page 40: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/40.jpg)
Quality of anesthesia (2)
![Page 41: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/41.jpg)
Duration of anesthesia
![Page 42: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/42.jpg)
Duration of analgesia
![Page 43: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/43.jpg)
Lidocaine and prilocaine periodontal gel (Oraqix)
![Page 44: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/44.jpg)
Disclaimers
Some of the information presented here was developed by Dentsply
I was a single-site principal investigator for one multisite phase 3 trial of Oraqix
Dentsply has provided a gift to UCLA for me to develop a DVD-based local anesthesia learning resource
![Page 45: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/45.jpg)
Lidocaine and prilocaine periodontal gel 2.5%/2.5%(Oraqix)
Eutectic mixture of local anesthetics
Solution at room temperature; gel at body temperature
First topical anesthetic specifically designed for scaling and root planing
FDA approved December 19, 2003 http://www.oraqix.com
![Page 46: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/46.jpg)
![Page 47: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/47.jpg)
Lidocaine and prilocaine periodontal gel 2.5%/2.5%(Oraqix)
Eutectic mixture of local anesthetics
Solution at room temperature; gel at body temperature
First topical anesthetic specifically designed for scaling and root planing
FDA approved December 19, 2003
![Page 48: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/48.jpg)
Oraqix delivery syringe
![Page 49: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/49.jpg)
Oraqix cartridge contents
Lidocaine/prilocaine 2.5%/2.5% Poloxamers 188 and 407 HCl for pH adjustment Purified water pH 7.5-8.0
![Page 50: Anxiety and Pain Control 2007 John A. Yagiela, DDS, PhD Utah Dental Association Salt Lake City February 9, 2007.](https://reader035.fdocuments.net/reader035/viewer/2022062802/56649e9c5503460f94b9d089/html5/thumbnails/50.jpg)